Hemodynamic and Biochemical Effects of the AT1 Receptor Antagonist Irbesartan in Hypertension
AH van den Meiracker, PJJ Admiraal, JA Janssen… - …, 1995 - Am Heart Assoc
We studied the hemodynamic, neurohumoral, and biochemical effects of the novel
angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with
essential hypertension on a normal sodium diet. According to a double-blind parallel group
trial, patients were randomized to a once-daily oral dose of the AT1 receptor antagonist (1,
25, or 100 mg) or placebo after a placebo run-in period of 3 weeks. Randomization
medication was given for 1 week. Compared with placebo, 24-hour ambulatory blood …
angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with
essential hypertension on a normal sodium diet. According to a double-blind parallel group
trial, patients were randomized to a once-daily oral dose of the AT1 receptor antagonist (1,
25, or 100 mg) or placebo after a placebo run-in period of 3 weeks. Randomization
medication was given for 1 week. Compared with placebo, 24-hour ambulatory blood …
Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension
P Admiraal, J Janssen, JM Kroodsma, W de Ronde… - Hypertension, 1995 - repub.eur.nl
We studied the hemodynamic, neurohumoral, and biochemical effects of the novel
angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with
essential hypertension on a normal sodium diet. According to a double-blind parallel group
trial, patients were randomized to a once-daily oral dose of the AT1 receptor antagonist (1,
25, or 100 mg) or placebo after a placebo run-in period of 3 weeks. Randomization
medication was given for 1 week. Compared with placebo, 24-hour ambulatory blood …
angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with
essential hypertension on a normal sodium diet. According to a double-blind parallel group
trial, patients were randomized to a once-daily oral dose of the AT1 receptor antagonist (1,
25, or 100 mg) or placebo after a placebo run-in period of 3 weeks. Randomization
medication was given for 1 week. Compared with placebo, 24-hour ambulatory blood …
以上显示的是最相近的搜索结果。 查看全部搜索结果